Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Engelman

Showing results (211-220 of 238) with videos related to

Pageof 24
Sort By:
Cancer Cell|October 8, 2021
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigmsHaichuan Hu, Zofia Piotrowska, Patricia J Hare, et al.
Cancer Research|June 18, 2016
Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal CancerDaniele Oddo, Erin M Sennott, Ludovic Barault, et al.
JCO Precision Oncology|January 30, 2018
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNAIbiayi Dagogo-Jack, A Rose Brannon, Lorin A Ferris, et al.
Nature Communications|March 12, 2015
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancerMatthew J Niederst, Lecia V Sequist, John T Poirier, et al.
Nature Communications|June 28, 2023
A landscape of response to drug combinations in non-small cell lung cancerNishanth Ulhas Nair, Patricia Greninger, Xiaohu Zhang, et al.
Nature Communications|February 18, 2016
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpointsShohei Koyama, Esra A Akbay, Yvonne Y Li, et al.
Cancer Cell|June 15, 2010
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumorsJulian Carretero, Takeshi Shimamura, Klarisa Rikova, et al.
Nature Medicine|March 6, 2018
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitorsLeila Dardaei, Hui Qin Wang, Manrose Singh, et al.
Cancer Discovery|July 20, 2016
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung CancerJustin F Gainor, Leila Dardaei, Satoshi Yoda, et al.
Nature Medicine|February 2, 2016
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibitionAaron N Hata, Matthew J Niederst, Hannah L Archibald, et al.
Pageof 24

Showing results (211-220 of 238) with videos related to

Sort By:
Pageof 24
Cancer Cell|October 8, 2021
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigmsHaichuan Hu, Zofia Piotrowska, Patricia J Hare, et al.
Cancer Research|June 18, 2016
Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal CancerDaniele Oddo, Erin M Sennott, Ludovic Barault, et al.
JCO Precision Oncology|January 30, 2018
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNAIbiayi Dagogo-Jack, A Rose Brannon, Lorin A Ferris, et al.
Nature Communications|March 12, 2015
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancerMatthew J Niederst, Lecia V Sequist, John T Poirier, et al.
Nature Communications|June 28, 2023
A landscape of response to drug combinations in non-small cell lung cancerNishanth Ulhas Nair, Patricia Greninger, Xiaohu Zhang, et al.
Nature Communications|February 18, 2016
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpointsShohei Koyama, Esra A Akbay, Yvonne Y Li, et al.
Cancer Cell|June 15, 2010
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumorsJulian Carretero, Takeshi Shimamura, Klarisa Rikova, et al.
Nature Medicine|March 6, 2018
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitorsLeila Dardaei, Hui Qin Wang, Manrose Singh, et al.
Cancer Discovery|July 20, 2016
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung CancerJustin F Gainor, Leila Dardaei, Satoshi Yoda, et al.
Nature Medicine|February 2, 2016
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibitionAaron N Hata, Matthew J Niederst, Hannah L Archibald, et al.
Pageof 24